Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease

The antifibrotic therapies nintedanib and pirfenidone were first approved by the United States for the treatment of idiopathic pulmonary fibrosis in 2014. In 2020, nintedanib received U.S. Food and Drug Administration (FDA) approval for the treatment of all progressive fibrosing interstitial lung di...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Musculoskeletal Disease 2021-12, Vol.13, p.1759720X211060907-1759720X211060907
Main Authors: Wilfong, Erin M., Aggarwal, Rohit
Format: Article
Language:English
Subjects:
Inflammatory diseases
Inhibitor drugs
Interferon
Interstitial Lung Disease in Autoimmune Rheumatic Disorders
Lung diseases
Musculoskeletal diseases
Pulmonary fibrosis
Respiratory failure
Scars
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c532t-62363116b959d1a3f5b931066f53253e43294c4762689c36e9b211bba702a2423
cites cdi_FETCH-LOGICAL-c532t-62363116b959d1a3f5b931066f53253e43294c4762689c36e9b211bba702a2423
container_end_page 1759720X211060907
container_issue
container_start_page 1759720X211060907
container_title Therapeutic Advances in Musculoskeletal Disease
container_volume 13
creator Wilfong, Erin M.
Aggarwal, Rohit
description The antifibrotic therapies nintedanib and pirfenidone were first approved by the United States for the treatment of idiopathic pulmonary fibrosis in 2014. In 2020, nintedanib received U.S. Food and Drug Administration (FDA) approval for the treatment of all progressive fibrosing interstitial lung disease (ILD). Given that a major cause of mortality and morbidity in the idiopathic inflammatory myopathies (IIM) is progressive interstitial lung disease and respiratory failure, antifibrotic therapies may be useful as adjuvant to traditional immunosuppression. However, randomized controlled trials of antifibrotic therapies in IIM are lacking. The purpose of this review is to (1) summarize the mechanism of action of nintedanib and pirfenidone in ILD with possible role in IIM-ILD, (2) review the clinical data supporting their use in interstitial lung disease in general, and more specifically in connective tissue disease associated ILD, and (3) discuss the evidence and remaining challenges for using antifibrotic therapies in IIM-ILD.
doi_str_mv 10.1177/1759720X211060907
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8876fec493054cca98d426dd302c8218</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1759720X211060907</sage_id><doaj_id>oai_doaj_org_article_8876fec493054cca98d426dd302c8218</doaj_id><sourcerecordid>2613246169</sourcerecordid><originalsourceid>FETCH-LOGICAL-c532t-62363116b959d1a3f5b931066f53253e43294c4762689c36e9b211bba702a2423</originalsourceid><addsrcrecordid>eNp1kltrFDEUgAdR2lr7A3yRgC--bM1tksmLIMVLoSBIhb6FM0lmN0tmsiaZwv57s7vtahWfEs758iXn5DTNa4IvCZHyPZGtkhTfUUKwwArLZ83ZLraQlHTPj3t8d9q8zHmNsVBYkZPmlHFFZDWcNZvvMTgUBwRT8YPvUyzeZOQnVFYOjTDB0o1uKjvEWx83UFbe1PwQYByhxLRF43Yf3iLIORoPxdkKFJdy8cVDQGGelsj67CC7V82LAUJ2Fw_refPj86fbq6-Lm29frq8-3ixMy2hZCMoEI0T0qlWWABvaXrFapRhqumWOM6q44VJQ0SnDhFN97ULfg8QUKKfsvLk-eG2Etd4kP0La6ghe7wMxLTWkWmtwuuukGJzhiuGWGwOqs5wKaxmmpqudrK4PB9dm7kdnTe1HgvBE-jQz-ZVexnvdCaE6oarg3YMgxZ-zy0WPPhsXAkwuzllTUUttKykr-vYvdB3nNNVW7ShGuSB7ITlQJsWckxuOjyFY72ZD_zMb9cybP6s4nngchgpcHoBcP_33tf83_gKYBcIi</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2613246169</pqid></control><display><type>article</type><title>Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease</title><source>SAGE Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Wilfong, Erin M. ; Aggarwal, Rohit</creator><creatorcontrib>Wilfong, Erin M. ; Aggarwal, Rohit</creatorcontrib><description>The antifibrotic therapies nintedanib and pirfenidone were first approved by the United States for the treatment of idiopathic pulmonary fibrosis in 2014. In 2020, nintedanib received U.S. Food and Drug Administration (FDA) approval for the treatment of all progressive fibrosing interstitial lung disease (ILD). Given that a major cause of mortality and morbidity in the idiopathic inflammatory myopathies (IIM) is progressive interstitial lung disease and respiratory failure, antifibrotic therapies may be useful as adjuvant to traditional immunosuppression. However, randomized controlled trials of antifibrotic therapies in IIM are lacking. The purpose of this review is to (1) summarize the mechanism of action of nintedanib and pirfenidone in ILD with possible role in IIM-ILD, (2) review the clinical data supporting their use in interstitial lung disease in general, and more specifically in connective tissue disease associated ILD, and (3) discuss the evidence and remaining challenges for using antifibrotic therapies in IIM-ILD.</description><identifier>ISSN: 1759-720X</identifier><identifier>EISSN: 1759-7218</identifier><identifier>DOI: 10.1177/1759720X211060907</identifier><identifier>PMID: 34917177</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Inflammatory diseases ; Inhibitor drugs ; Interferon ; Interstitial Lung Disease in Autoimmune Rheumatic Disorders ; Lung diseases ; Musculoskeletal diseases ; Pulmonary fibrosis ; Respiratory failure ; Scars</subject><ispartof>Therapeutic Advances in Musculoskeletal Disease, 2021-12, Vol.13, p.1759720X211060907-1759720X211060907</ispartof><rights>The Author(s), 2021</rights><rights>The Author(s), 2021.</rights><rights>The Author(s), 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s), 2021 2021 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c532t-62363116b959d1a3f5b931066f53253e43294c4762689c36e9b211bba702a2423</citedby><cites>FETCH-LOGICAL-c532t-62363116b959d1a3f5b931066f53253e43294c4762689c36e9b211bba702a2423</cites><orcidid>0000-0002-6584-1578</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669869/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2613246169?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,21966,25753,27853,27922,27924,27925,37012,37013,44590,44945,45333,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34917177$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilfong, Erin M.</creatorcontrib><creatorcontrib>Aggarwal, Rohit</creatorcontrib><title>Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease</title><title>Therapeutic Advances in Musculoskeletal Disease</title><addtitle>Ther Adv Musculoskelet Dis</addtitle><description>The antifibrotic therapies nintedanib and pirfenidone were first approved by the United States for the treatment of idiopathic pulmonary fibrosis in 2014. In 2020, nintedanib received U.S. Food and Drug Administration (FDA) approval for the treatment of all progressive fibrosing interstitial lung disease (ILD). Given that a major cause of mortality and morbidity in the idiopathic inflammatory myopathies (IIM) is progressive interstitial lung disease and respiratory failure, antifibrotic therapies may be useful as adjuvant to traditional immunosuppression. However, randomized controlled trials of antifibrotic therapies in IIM are lacking. The purpose of this review is to (1) summarize the mechanism of action of nintedanib and pirfenidone in ILD with possible role in IIM-ILD, (2) review the clinical data supporting their use in interstitial lung disease in general, and more specifically in connective tissue disease associated ILD, and (3) discuss the evidence and remaining challenges for using antifibrotic therapies in IIM-ILD.</description><subject>Inflammatory diseases</subject><subject>Inhibitor drugs</subject><subject>Interferon</subject><subject>Interstitial Lung Disease in Autoimmune Rheumatic Disorders</subject><subject>Lung diseases</subject><subject>Musculoskeletal diseases</subject><subject>Pulmonary fibrosis</subject><subject>Respiratory failure</subject><subject>Scars</subject><issn>1759-720X</issn><issn>1759-7218</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kltrFDEUgAdR2lr7A3yRgC--bM1tksmLIMVLoSBIhb6FM0lmN0tmsiaZwv57s7vtahWfEs758iXn5DTNa4IvCZHyPZGtkhTfUUKwwArLZ83ZLraQlHTPj3t8d9q8zHmNsVBYkZPmlHFFZDWcNZvvMTgUBwRT8YPvUyzeZOQnVFYOjTDB0o1uKjvEWx83UFbe1PwQYByhxLRF43Yf3iLIORoPxdkKFJdy8cVDQGGelsj67CC7V82LAUJ2Fw_refPj86fbq6-Lm29frq8-3ixMy2hZCMoEI0T0qlWWABvaXrFapRhqumWOM6q44VJQ0SnDhFN97ULfg8QUKKfsvLk-eG2Etd4kP0La6ghe7wMxLTWkWmtwuuukGJzhiuGWGwOqs5wKaxmmpqudrK4PB9dm7kdnTe1HgvBE-jQz-ZVexnvdCaE6oarg3YMgxZ-zy0WPPhsXAkwuzllTUUttKykr-vYvdB3nNNVW7ShGuSB7ITlQJsWckxuOjyFY72ZD_zMb9cybP6s4nngchgpcHoBcP_33tf83_gKYBcIi</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Wilfong, Erin M.</creator><creator>Aggarwal, Rohit</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6584-1578</orcidid></search><sort><creationdate>20211201</creationdate><title>Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease</title><author>Wilfong, Erin M. ; Aggarwal, Rohit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c532t-62363116b959d1a3f5b931066f53253e43294c4762689c36e9b211bba702a2423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Inflammatory diseases</topic><topic>Inhibitor drugs</topic><topic>Interferon</topic><topic>Interstitial Lung Disease in Autoimmune Rheumatic Disorders</topic><topic>Lung diseases</topic><topic>Musculoskeletal diseases</topic><topic>Pulmonary fibrosis</topic><topic>Respiratory failure</topic><topic>Scars</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilfong, Erin M.</creatorcontrib><creatorcontrib>Aggarwal, Rohit</creatorcontrib><collection>SAGE Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Therapeutic Advances in Musculoskeletal Disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilfong, Erin M.</au><au>Aggarwal, Rohit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease</atitle><jtitle>Therapeutic Advances in Musculoskeletal Disease</jtitle><addtitle>Ther Adv Musculoskelet Dis</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>13</volume><spage>1759720X211060907</spage><epage>1759720X211060907</epage><pages>1759720X211060907-1759720X211060907</pages><issn>1759-720X</issn><eissn>1759-7218</eissn><abstract>The antifibrotic therapies nintedanib and pirfenidone were first approved by the United States for the treatment of idiopathic pulmonary fibrosis in 2014. In 2020, nintedanib received U.S. Food and Drug Administration (FDA) approval for the treatment of all progressive fibrosing interstitial lung disease (ILD). Given that a major cause of mortality and morbidity in the idiopathic inflammatory myopathies (IIM) is progressive interstitial lung disease and respiratory failure, antifibrotic therapies may be useful as adjuvant to traditional immunosuppression. However, randomized controlled trials of antifibrotic therapies in IIM are lacking. The purpose of this review is to (1) summarize the mechanism of action of nintedanib and pirfenidone in ILD with possible role in IIM-ILD, (2) review the clinical data supporting their use in interstitial lung disease in general, and more specifically in connective tissue disease associated ILD, and (3) discuss the evidence and remaining challenges for using antifibrotic therapies in IIM-ILD.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>34917177</pmid><doi>10.1177/1759720X211060907</doi><orcidid>https://orcid.org/0000-0002-6584-1578</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1759-720X
ispartof Therapeutic Advances in Musculoskeletal Disease, 2021-12, Vol.13, p.1759720X211060907-1759720X211060907
issn 1759-720X
1759-7218
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_8876fec493054cca98d426dd302c8218
source SAGE Open Access; Publicly Available Content Database; PubMed Central
subjects Inflammatory diseases
Inhibitor drugs
Interferon
Interstitial Lung Disease in Autoimmune Rheumatic Disorders
Lung diseases
Musculoskeletal diseases
Pulmonary fibrosis
Respiratory failure
Scars
title Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T10%3A19%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20antifibrotics%20in%20the%20management%20of%20idiopathic%20inflammatory%20myopathy%20associated%20interstitial%20lung%20disease&rft.jtitle=Therapeutic%20Advances%20in%20Musculoskeletal%20Disease&rft.au=Wilfong,%20Erin%20M.&rft.date=2021-12-01&rft.volume=13&rft.spage=1759720X211060907&rft.epage=1759720X211060907&rft.pages=1759720X211060907-1759720X211060907&rft.issn=1759-720X&rft.eissn=1759-7218&rft_id=info:doi/10.1177/1759720X211060907&rft_dat=%3Cproquest_doaj_%3E2613246169%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c532t-62363116b959d1a3f5b931066f53253e43294c4762689c36e9b211bba702a2423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2613246169&rft_id=info:pmid/34917177&rft_sage_id=10.1177_1759720X211060907&rfr_iscdi=true